No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > LRRC15


Brief Information

Name:Leucine-rich repeat-containing protein 15
Target Synonym:LRRC15,Leucine-rich repeat-containing protein 15,hLib,Leucine Rich Repeat Containing 15,Leucine-Rich Repeat Protein Induced By Beta-Amyloid Homolog,LIB,Leucine-Rich Repeat Protein Induced By Beta Amyloid
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:0
Lastest Research Phase:Preclinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CHEK-ATP123-Cell-based assay

Expression analysis of human LRRC15 on HEK293/Human LRRC15 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human LRRC15 Stable Cell Line or negative control cell using anti-human LRRC15 antibody followed by staining with FITC anti-mouse IgG antibody.


Immobilized Cynomolgus / Rhesus macaque LRRC15 Protein, Fc Tag (Cat. No. LR5-C5253) at 10 μg/mL (100 μL/well) can bind Samrotamab with a linear range of 0.3-4 ng/mL (QC tested).

LRRC15 MALS images

The purity of Biotinylated Rat LRRC15 Protein, His,Avitag (Cat. No. LR5-R82E3) is more than 90% and the molecular weight of this protein is around 75-95 kDa verified by SEC-MALS.

Synonym Name

Leucine-rich repeat-containing protein 15,LRRC15,LIB,hLib


LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

Clinical and Translational Updates

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Correo electrónico
+1 888-377-6111
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje